To Evaluate Effectiveness and Safety of Containing Raltegravir in Naive HIV NON B or B Infected Patients (Ral'inNONB)
|ClinicalTrials.gov Identifier: NCT01162538|
Recruitment Status : Unknown
Verified May 2010 by Centre Hospitalier Intercommunal Robert Ballanger.
Recruitment status was: Not yet recruiting
First Posted : July 14, 2010
Last Update Posted : July 14, 2010
|Condition or disease|
|Evaluated Non B Subtype Naive Patients|
The population VIH1 not B is not unimportant in our region of the Seine St Denis, a tendency which seems to be in increase (47 % in 2006, 67 % in 2007).
Most of the studies evaluating the clinical, immunologic and virologic response to the ARV according to the viral subcategories are corresponding and show comparable results for patients infected by HIV 1 of subcategory B or non B. In spite of these reassuring results, it is necessary to evaluate the efficiency of a new ARV all the more a new class. It seems also necessary to observe attentively the profiles of resistance which will be selected at the carrier patient's of virus of subcategories not - B in failure of treatment. It will allow to determine if, because of the important polymorphisms of the viruses not - B, the evolution towards the resistance will be made differently.
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||The Main Objective of This Study is to Evaluate the Virologic Effectiveness at M6 of Regimen Containing Raltegravir in Treatment Naive HIV Subtype Non B or B Infected Subjects|
|Study Start Date :||September 2010|
|Estimated Primary Completion Date :||March 2011|
|Estimated Study Completion Date :||March 2012|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01162538
|Hopital R.Ballanger||Not yet recruiting|
|Aulnay sous Bois, France, 93602|
|Contact: Delassus Jean-Luc, MD 1 49 36 72 81 ext +33 email@example.com|
|Principal Investigator:||Delassus Jean-Luc, MD||Réseau Aulnay 93|